Calithera Biosciences, Inc. (NASDAQ:CALA) Short Interest Down 12.1% in January

kopsource · Feb 17, 2023 09:31

Calithera Biosciences, Inc. (NASDAQ:CALA – Get Rating) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 366,600 shares, a drop of 12.1% from the January 15th total of 417,300 shares. Approximately 7.7% of the company's stock are sold short. Based on an average daily volume of 309,500 shares, the days-to-cover ratio is presently 1.2 days.

Calithera Biosciences Price Performance

CALA stock remained flat at $0.09 during midday trading on Thursday. The company had a trading volume of 104,173 shares, compared to its average volume of 564,955. The stock has a market capitalization of $440,491.50, a P/E ratio of 0.00 and a beta of 1.05. The company's fifty day simple moving average is $1.27 and its 200 day simple moving average is $2.40. Calithera Biosciences has a fifty-two week low of $0.07 and a fifty-two week high of $13.38.

Get Calithera Biosciences alerts:

Calithera Biosciences (NASDAQ:CALA – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The biotechnology company reported ($2.01) EPS for the quarter, missing analysts' consensus estimates of ($1.99) by ($0.02). Research analysts anticipate that Calithera Biosciences will post -8.62 EPS for the current year.

Insider Buying and Selling at Calithera Biosciences

In other news, Director Deepika Pakianathan sold 121,333 shares of Calithera Biosciences stock in a transaction that occurred on Friday, January 27th. The stock was sold at an average price of $0.39, for a total transaction of $47,319.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.60% of the company's stock.

Institutional Trading of Calithera Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its position in shares of Calithera Biosciences by 36.5% during the 1st quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock worth $749,000 after buying an additional 496,100 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Calithera Biosciences in the first quarter valued at about $404,000. Affinity Asset Advisors LLC bought a new position in Calithera Biosciences in the first quarter valued at about $404,000. Vanguard Group Inc. raised its position in Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock valued at $415,000 after purchasing an additional 26,800 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Calithera Biosciences by 143.2% in the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 72,865 shares during the last quarter. 33.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. StockNews.com assumed coverage on Calithera Biosciences in a research report on Wednesday. They set a "hold" rating on the stock. SVB Leerink cut Calithera Biosciences from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 15th. Finally, LADENBURG THALM/SH SH cut Calithera Biosciences from a "buy" rating to a "neutral" rating in a research report on Tuesday, November 15th.

About Calithera Biosciences

(Get Rating)

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.